Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer

Thyroid

Volumn 20, Issue 9, 2010, Pages 965-974

  Fenton, Mike S ^a   Marion, Kenneth M ^a   Salem, Andrew K ^a   Hogen, Rachel ^a   Naeim, Faramarz ^a   Hershman, Jerome M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; FORSKOLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RETINOBLASTOMA PROTEIN; SODIUM IODIDE SYMPORTER; STRESS ACTIVATED PROTEIN KINASE; SUNITINIB; SYNAPTOPHYSIN; UO 126;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; DRUG INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYROID CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INDOLES; MAP KINASE KINASE 4; PROTEIN KINASE INHIBITORS; PYRROLES; SIGNAL TRANSDUCTION; SYMPORTERS; THYROID NEOPLASMS;

EID: 77956509424     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0008     Document Type: Article

References (27)

1. Dulgeroff AJ, Hershman JM 1994 Medical therapy for differentiated thyroid carcinoma. Endocr Rev 15:500-515.
2. Vitagliano D, Carlomagno F, Motti ML, Viglietto G, Nikiforov YE, Nikiforova MN, Hershman JM, Ryan AJ, Fusco A, Melillo RM, Santoro M 2004 Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res 64:3823-3829.
3. Hwang JH, Kim DW, Suh JM, Kim H, Song JH, Hwang ES, Park KC, Chung HK, Kim JM, Lee TH, Yu DY, Shong M 2003 Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/ papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. Mol Endocrinol (Baltimore, Md) 17:1155-1166.
4. Ohta K, Pang XP, Berg L, Hershman JM 1997 Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor. J Clin Endocrinol Metab 82:2633-2638.
5. Taki K, Kogai T, Kanamoto Y, Hershman JM, Brent GA 2002 A thyroid-specific far-upstream enhancer in the human sodium/iodide symporter gene requires Pax-8 binding and cyclic adenosine 3,5-monophosphate response element-like sequence binding proteins for full activity and is differentially regulated in normal and thyroid cancer cells. Mol Endocrinol (Baltimore, Md) 16:2266-2282.
6. Fenton MS, Marion KM, Hershman JM 2008 Identification of CREM as an activator of the human Na+/I- symporter (NIS) upstream enhancer (NUE). Endocrinology 149:2592-2606.
7. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M 2006 An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 91:4070-4076.
8. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow L, Copland JA, Smallridge RC, Haugen BR 2008 DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 93:4331-4341.
9. Weeraratna AT, Jiang Y, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM 2002 Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1:279-288.
10. An J, Sun Y, Fisher M, Rettig MB 2004 Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent. Mol Cancer Ther 3:727-736.
11. Rozen S, Skaletsky H 2000 Primer3 on the WWWfor general users and for biologist programmers. In: Krawetz S, Misener S (eds) Bioinformatics Methods and Protocols: Methods in Molecular Biology. Humana Press, Totowa, NJ.
12. Kogai T, Kanamoto Y, Li AI, Che LH, Ohashi E, Taki K, Chandraratna RA, Saito T, Brent GA 2005 Differential regulation of sodium/iodide symporter gene expression by nuclear receptor ligands in MCF-7 breast cancer cells. Endocrinology 146:3059-3069.
13. Knauf JA, Kuroda H, Basu S, Fagin JA 2003 RET/PTCinduced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22:4406-4412.
14. Knauf JA, Ouyang B, Croyle M, Kimura E, Fagin JA 2003 Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells. Oncogene 22:6830-6838.
15. Salem AK, Fenton MS, Marion KM, Hershman JM 2008 Effect of sunitinib on growth and function of FRTL-5 thyroid cells. Thyroid 18:631-635.
16. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337.
17. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Jr., Knauf JA, Zhang L, Taira K, Fagin JA 2006 BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147:1014-1019.
18. De Falco V, Castellone MD, De Vita G, Cirafici AM, Hershman JM, Guerrero C, Fusco A, Melillo RM, Santoro M 2007 RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. Cancer Res 67:381-390.
19. Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG, Filetti S 1998 Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 83:2493-2496.
20. Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, Bidart JM 1998 Na+/I- symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 83:4102-4106.
21. Ryu KY, Senokozlieff ME, Smanik PA, Wong MG, Siperstein AE, Duh QY, Clark OH, Mazzaferri EL, Jhiang SM 1999 Development of reverse transcription- competitive polymerase chain reaction method to quantitate the expression levels of human sodium iodide symporter. Thyroid 9:405-409.
22. Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM 1997 Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 138:3555-3558.
23. Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N 2001 Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 86:2697-2700.
24. Dohan O, Carrasco N 2003 Advances in Na(+)/I(-) symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol 213:59-70.
25. Xing M 2007 BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 28:742-762.
26. Cahill S, Smyth P, Finn SP, Denning K, Flavin R, ORegan EM, Li J, Potratz A, Guenther SM, Henfrey R, OLeary JJ, Sheils O 2006 Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer 5:70.
27. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE 2008 MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93:1600-1608.